27 February 2026 - Asieris Pharmaceuticals announced today that its marketing authorisation application for APL-1702 (Cevira) for the treatment of high grade squamous intraepithelial lesions has been accepted by the EMA.

APL-1702 is a globally first in class, China originated photodynamic therapy product.

Read Asieris Pharmaceuticals press release